We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Covering thalidomide, lenalidomide, and pomalidomide: temporary guidance for pregnancy prevention arrangements for patients taking them during COVID-19
Healthcare professionals should consider the possibility of second primary malignancy in patients treated with lenalidomide.
Routine monitoring of liver function now recommended.
Patients receiving lenalidomide for management of multiple myeloma should be closely monitored for evidence of arterial and venous thromboembolic events.
Healthcare professionals should consider this risk when deciding whether to treat patients with thalidomide monitor for the occurrence of these conditions.
Guidance has been published about thalidomide, lenalidomide, and pomalidomide and the use of remote consultations and home pregnancy testing for patients taking them during COVID-19.
Before starting treatment with pomalidomide, establish hepatitis B virus status in all patients.
Neon Healthcare Ltd is recalling the specific batch mentioned in this notification as a precautionary measure.
Information for patients, healthcare professionals and developers of new medicines
You must get permission to export certain drugs and medicines.
A summary of recent letters sent to relevant healthcare professionals, to inform them of updated safety information.
The UK condemns Russia's use of arbitrary detention and calls for an immediate and unconditional release of Ukrainian civilian detainees. Statement on Moscow Mechanism Report.
medac GmbH (t/a medac Pharma LLP) is recalling the product for the batch specified in this notification due to particles detected during long-term stability tests.
A. Menarini Farmaceutica Internazionale Srl is recalling a specific batch as a precautionary measure due to the distribution of Invokana 300mg in Northern Ireland in packaging intended for the Greek market.
Establish hepatitis B status before initiating carfilzomib and in patients with unknown hepatitis B virus serology who are already being treated with carfilzomib.
Product Recall for Vincenza Jewellery Pave Zircon Initial Cord Bracelet presenting a serious chemical risk.
Check the tariff classification for surface-active preparation for washing the skin and the hair (gel 2-in-1).
Product Safety Report for SIVOP Parfums & Cosmétiques Clair-Liss Lightening Body Cream presenting a serious chemical risk.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.